Browse by Administration Route

This page shows data for Oral virus.
Total Entries Retrieved: 14
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10138 RotaTeq (RV5) Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved Merck & Co. Inc. NA USA 6 months - 8 months 3 doses at age of 2 months, 4 months, and 6 months Oral NA 5 human-bovine reassortant rotaviruses (G1, G2, G3 G4, P[8]) NA US FDA NA NA NA NA NA https://www.cdc.gov/vaccines/vpd/rotavirus/index.html https://www.fda.gov/media/75718/download
10139 Rotarix (RV1) Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved GlaxoSmithKline 2006 UK 6 months - 8 months 2 doses at ages 2 months and 4 months Oral NA Human rotavirus strain (G1P[8]) NA US FDA, EMA NA NA NA NA NA https://www.cdc.gov/vaccines/vpd/rotavirus/index.html https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
10140 Rotavac Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved Bharat Biotech International Limited 2013 India 6 months - 8 months 3 doses 4 weeks apart Oral NA Rotavirus 116E strain NA US FDA, Government of India NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://www.fda.gov/vaccines-blood-biologics/vaccines/rotavirus-vaccine-live-oral
10141 RotaSiil Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Approved Serum Institute of India 2017 India 6 months - 8 months 3 doses 4 weeks apart Oral NA Human-bovine reassortant rotaviruses (G1, G2, G3, G4, G9) NA National Institute of Health, Government of India NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
10142 BL 125296 Adenovirus Infection Respiratory Adenovirus Type 4, Type 7 double stranded DNA Live-attenuated Approved Barr Pharmaceuticals Inc. NA USA 17 - 50 years 2 doses Oral NA Live adenovirus NA US FDA NA NA NA NA NA https://www.fda.gov/media/80211/download https://www.fda.gov/vaccines-blood-biologics/vaccines/adenovirus-type-4-and-type-7-vaccine-live-oral
10152 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA 18 - 59 years NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 32585611 NCT04334980 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10156 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 55 years 2 doses 28 days apart Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33937326 NCT04563702 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10157 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 54 years 2 doses 28 days apart Oral NA NA Ad5 adjuvanted Oral Vaccine platform NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10164 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA NA Single dose Oral NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10186 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation 2020 Australia 18 years and above NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04334980 https://clinicaltrials.gov/show/NCT04334980 NA
10286 V-SARS COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Plasma based Phase 2 Immunitor LLC 2020 Canada 18 - 65 years NA Oral NA Pooled plasma of COVID-19 patients NA NA NA NA NA NA NCT04380532 https://clinicaltrials.gov/show/NCT04380532 NA
10312 RV3-BB Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 2 PT Biofarma NA Indonesia 0 - 5 days 3 doses regimen child schedule (0 to 5 days, 8 weeks, and 14 weeks of age or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age) Oral NA Three VP8 subunit proteins expressing P[4], P[6] and P[8] serotypes NA NA NA NA NA NA NA https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf NA
10377 Lamb rotavirus Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 4 Lanzhou Biologicals 2000 China 6 months - 35 months NA Oral NA Single strain of rotavirus found in lamb (G10P) NA NA NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
10378 ROTAVIN-M1 Rotavirus Infection Gastrointestinal Rotavirus double stranded RNA Live-attenuated Phase 4 Polyvac, Center for Research and Production of Vaccines NA Vietnam 6 months - 8 months NA Oral NA Human rotavirus strain (G1P) NA NA NA NA NA NA NA https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1 https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf